New Guidelines for Mild-to-Moderate Ulcerative Colitis Treatment
The American Gastroenterological Association has published new clinical guidelines for treating mild-to-moderate ulcerative colitis (UC), an inflammatory bowel disease (IBD). Mild-to-moderate UC, characterized by periods of disease activity followed by periods of remission, is defined by these symptoms:
Fewer than four to six bowel movements per day
Mild or moderate rectal bleeding
Absence of symptoms like fever, fatigue, weight loss, or malaise
Low, rather than high, levels of inflammatory activity
The new guidelines, published in Gastroenterology, focus on the use of oral and topical 5-aminosalicylates (5-ASA) medications (sulfasalazine, mesalamine, balsalazide, olsalazine), rectal corticosteroids, and oral budesonide (Entocort EC, Uceris). People with ulcerative colitis who don’t respond to these therapies may require a stronger medication regimen, but the new guidelines don’t address these treatments.
Sourced from: Gastroenterology